By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Emergent BioSolutions 

2273 Research Boulevard
Suite 400
Rockville  Maryland  20850  U.S.A.
Phone: 301-795-1800 Fax: 301-795-1899

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.

Key Statistics

Ownership: Public

Web Site: Emergent BioSolutions
Symbol: EBS

Company News
Emergent BioSolutions (EBS) Snags $44 Million CDC Contract to Further Advance Vaccinia Immune Globulin Intravenous Program 8/13/2015 6:19:08 AM
Emergent BioSolutions (EBS) Reports Second Quarter And Six Months 2015 Financial Results And Reaffirms 2015 Guidance 8/6/2015 2:08:39 PM
Emergent BioSolutions (EBS) to Spin Off Immuno-Oncology Company in 2016 8/6/2015 7:41:12 AM
Emergent BioSolutions (EBS) Expands Biodefense Business Through Launch Of A Military-Grade Auto-Injector Device For Chemical Threats 8/3/2015 8:01:25 AM
Emergent BioSolutions (EBS) To Release Second Quarter 2015 Financial Results And Conduct A Conference Call On August 6, 2015 7/23/2015 8:19:27 AM
Emergent BioSolutions (EBS) Awarded $19.7 Million Biomedical Advanced Research and Development Authority (BARDA) Contract To Develop And Manufacture Ebola Monoclonal Antibodies 7/20/2015 7:24:55 AM
Emergent BioSolutions (EBS) Signs Long-Term Manufacturing Agreement With ProMetic Life Sciences Inc. (PFSCF.PK) 5/19/2015 8:36:45 AM
Emergent BioSolutions (EBS) To Hold Annual Meeting Of Stockholders Thursday May 21, 2015 At 9:00 AM Eastern; Webcast Will Be Available 5/14/2015 1:29:02 PM
Oxford University, GlaxoSmithKline (GSK) And Emergent BioSolutions (EBS) Announce Initiation Of A Prime Boost Study Of Ebola Vaccine Candidates 5/13/2015 7:43:05 AM
Soligenix (SNGX) Announces Development Agreement With Emergent BioSolutions (EBS) 5/13/2015 6:40:15 AM